AZD-1775, a drug that inhibits the G2–M cell-cycle checkpoint gatekeeper WEE1 kinase, has been used in multiple trials studying the treatment of lymphoma, ovarian cancer, and adult glioblastoma [32, 78]. This evidence concerns the gene WEE1 and glioblastoma.